{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:52:18Z","timestamp":1791150738508,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T00:00:00Z","timestamp":1411689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:p>Four hundred and nine patients with chronic myelomonocytic leukemia (CMML) were included in the international collaborative study (268 (66%) and 141 (34%) from Mayo clinic and French consortium respectively). Thirty percent displayed an abnormal karyotype, including; 72% sole, 16% two, and 11% complex abnormalities. The most common abnormalities included; +8 (23%), \u2010Y (20%), \u20107\/7q\u2010(14%), 20q\u2010 (8%), +21 (8%), and der(3q) (8%). Patients with an abnormal karyotype were more likely to be elderly (<jats:italic>P<\/jats:italic>\u2009=\u20090.03), be anemic (<jats:italic>P<\/jats:italic>\u2009=\u20090.0009), have leukocytosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.02) with neutrophilia (<jats:italic>P<\/jats:italic>\u2009=\u20090.03), demonstrate increased circulating immature myeloid cells (<jats:italic>P<\/jats:italic>\u2009=\u20090.0003), peripheral blood blasts (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), and bone marrow blasts (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). <jats:italic>ASXL1<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20090.04) and <jats:italic>SF3B1<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20090.03) mutations clustered with an abnormal karyotype, whereas <jats:italic>SRSF2<\/jats:italic> (<jats:italic>P<\/jats:italic>\u2009=\u20090.02) mutations occurred more commonly with a normal karyotype. A step\u2010wise survival analysis resulted in three distinct cytogenetic risk categories: high (complex and monosomal karyotypes), intermediate (all abnormalities not in the high or low risk groups) and low [normal, sole \u2010Y and sole der (3q)] with median survivals of 3 [hazard ratio (HR)\u2009=\u20098.1, 95% confidence interval (CI)\u2009=\u20094.6\u201314.2], 20 (HR\u2009=\u20091.7, 95% CI\u2009=\u20091.2\u20132.3) and 41 months, respectively. In multivariable analysis, this particular cytogenetic risk stratification remained significant in the context of the Molecular Mayo Model (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), MD Anderson prognostic model (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001), the GFM CMML model (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) and was effective in predicting leukemic transformation (<jats:italic>P<\/jats:italic>\u2009=\u20090.004). Am. J. Hematol. 89:1111\u20131115, 2014. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23846","type":"journal-article","created":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T10:17:19Z","timestamp":1410171439000},"page":"1111-1115","source":"Crossref","is-referenced-by-count":131,"title":["Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a <scp>M<\/scp>ayo <scp>C<\/scp>linic\u2010<scp>F<\/scp>rench <scp>C<\/scp>onsortium <scp>S<\/scp>tudy"],"prefix":"10.1002","volume":"89","author":[{"given":"Emnet A.","family":"Wassie","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Itzykson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Descartes Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Kosmider","sequence":"additional","affiliation":[{"name":"Institute Cochin Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy M.","family":"Finke","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Division of Cytogenetics Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Solary","sequence":"additional","affiliation":[{"name":"Institut Gustave Roussy Villejuif France"},{"name":"INSERM U1009 Villejuif France"},{"name":"Universit\u00e9 Paris\u2010Sud 11 Orsay France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,26]]},"reference":[{"key":"e_1_2_5_2_1","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swederlow S","year":"2008"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.840"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23373"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030957"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23751"},{"key":"e_1_2_5_7_1","article-title":"Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: A single\u2010institution experience","author":"Alsahlawi A","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.258"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-12"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-440347"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07697.x"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.88"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404863"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10496"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.064048"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020150"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1361"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.48"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311019"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.125"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12756"},{"key":"e_1_2_5_23_1","first-page":"1","article-title":"Report of the Standing Committee on Human Cytogenetic Nomenclature","volume":"21","author":"An International System for Human Cytogenetic Nomenclature (1985) ISCN 1985","year":"1985","journal-title":"Birth Defects Orig Artic Ser"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.88"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-377994"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0259"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.234"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2674"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2003.08.003"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23846","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23846","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:01:01Z","timestamp":1696636861000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,26]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1002\/ajh.23846"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23846","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,26]]}}}